376 results on '"Ding, Pei-Rong"'
Search Results
2. The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study
3. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial
4. Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study
5. Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients
6. Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors (TNTCRT): A multicenter, randomized, open-label, phase 3 trial.
7. Long-term outcomes of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): a randomized, multicenter, prospective, phase III trial
8. Long-Term Outcomes of dMMR/MSI-H Rectal Cancer Treated With Anti–PD-1–Based Immunotherapy as Curative-Intent Treatment
9. Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial
10. High dose chemoradiotherapy increases chance of organ preservation with satisfactory functional outcome for rectal cancer
11. Comprehensive profiling of 1015 patients’ exomes reveals genomic-clinical associations in colorectal cancer
12. Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer
13. Temporal Change in Treatment Patterns of Metastatic Colorectal Cancer and Its Association with Patient Survival: A Retrospective Cohort Study Based on an Intelligent Big-Data Platform
14. Histopathological growth patterns correlate with the immunoscore in colorectal cancer liver metastasis patients after hepatectomy
15. Comparisons of screening strategies for identifying Lynch syndrome among patients with MLH1-deficient colorectal cancer
16. The watch-and-wait strategy versus surgical resection for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy
17. Neoadjuvant chemoradiotherapy in patients with unresectable locally advanced sigmoid colon cancer: clinical feasibility and outcome
18. A fecal-based test for the detection of advanced adenoma and colorectal cancer: a case-control and screening cohort study
19. The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers
20. Screening and Management of Lynch Syndrome: The Chinese Experience
21. Application of Molecular Profiling in Colorectal Cancer Surgery
22. Update on Familial Adenomatous Polyposis-Associated Desmoid Tumors
23. Nonoperative Management of dMMR/MSI-H Colorectal Cancer following Neoadjuvant Immunotherapy: A Narrative Review
24. Dickkopf-related protein 1, a new biomarker for local immune status and poor prognosis among patients with colorectal liver Oligometastases: a retrospective study
25. The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases
26. Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair–Deficient Colorectal Cancer
27. Clinicopathological characteristics of high microsatellite instability/mismatch repair-deficient colorectal cancer: A narrative review
28. Neoadjuvant Chemotherapy with CAPOX versus Chemoradiation for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial
29. Multi-omics analyses of single cell-derived colorectal cancer organoids reveal intratumor heterogeneity and immune response diversity
30. Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer: A multicentre cohort study
31. Safety of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection: a randomized, multicenter, prospective, phase III IOCCRC trial (IOCCRC)
32. Patterns of recurrence in patients achieving pathologic complete response after neoadjuvant chemoradiotherapy for rectal cancer
33. Neoadjuvant Sandwich Treatment With Oxaliplatin and Capecitabine Administered Prior to, Concurrently With, and Following Radiation Therapy in Locally Advanced Rectal Cancer: A Prospective Phase 2 Trial
34. Clinical actionability of triaging DNA mismatch repair deficient colorectal cancer from biopsy samples using deep learning
35. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study
36. The prognostic impact of preoperative blood monocyte count in pathological T3N0M0 rectal cancer without neoadjuvant chemoradiotherapy
37. Neoadjuvant Immune Checkpoint Inhibition Improves Organ Preservation in T4bm0 Colorectal Cancer With Mismatch Repair Deficiency: A Retrospective Observational Study
38. Additional file 3 of High dose chemoradiotherapy increases chance of organ preservation with satisfactory functional outcome for rectal cancer
39. Additional file 2 of High dose chemoradiotherapy increases chance of organ preservation with satisfactory functional outcome for rectal cancer
40. Additional file 1 of High dose chemoradiotherapy increases chance of organ preservation with satisfactory functional outcome for rectal cancer
41. Tailored selection of the interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer: analysis based on the pathologic stage or chemoradiation response
42. A nomogram for predicting cancer specific survival (CSS) in patients with pathological T3N0M0 (pT3N0M0) rectal cancer.
43. SONCAR study: A prospective randomized controlled study on optimized neoadjuvant chemotherapy-oxaliplatin plus CRT in patients with locally advanced rectal cancer.
44. Simple measurements on diffusion-weighted MR imaging for assessment of complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
45. Selective use of adjuvant chemotherapy for rectal cancer patients with ypN0
46. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review
47. Inflammatory Conditions Promote Resistance to Immune Checkpoint Inhibitors in High Microsatellite Instability Colorectal Cancer
48. Corrigendum to “Voltage-gated sodium channel Nav1.5 promotes tumor progression and enhances chemosensitivity to 5-fluorouracil in colorectal cancer” [Canc. Lett. 500 (2021) 119-131]
49. Beneficiaries of radical surgery among clinical complete responders to neoadjuvant chemoradiotherapy in rectal cancer
50. Additional file 1 of The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.